《2018年血运重建指南》解读
摘要
<正>2018年8月欧洲心脏病学会(European Society of Cardiology,ESC)及欧洲心胸外科协会(European Association for Cardio-thoracic Surgery,EACTS)联合发布《2018年血运重建指南》~([1])(以下简称《新指南》),于2018年在ESC年会议上公布,并同步发表于European Heart Journal。这也是两大学术组织会在《2014年欧
引文
[1] Neumann FJ,Sousauva M,Ahlsson A,et al.2018 ESC/EACTSguidelines on myocardial revascularization[J]. Kardiol Pol,2018,76(12):1585-1664.
[2] Montalescot G,Sechtem U,Achenbach S,et al. 2013 ESC guidelines on the management of stable coronary artery[J]. Eur Heart J,2013(34):2949-3003.
[3] Bonow RO,Maurer G,Lee KL,et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction[J].NEnglJMed,2011(364):1617-1625.
[4] Allman KC,Shaw LJ,Hachamovitch R,et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction:A meta-analysis[J]. J Am Coll Cardiol,2002(39):1151-1158.
[5] Ling LF,Marwick TH,Flores DR,et al. Identification of therapeutic benefit from revascularization inpatients with left ventricular systolic dysfunction:Inducible ischemia versus hibernating myocardium[J]. Circ Cardiovasc Imaging,2013,6(3):363-372.
[6] Pijls NH,van Schaardenburgh P,Manoharan G,et al. Percutaneous coronaryintervention of functionally nonsignificant stenosis:5-year follow-up of the DEFER Study[J]. J Am CollCardiol, 2007(49):2105-2111.
[7] Davies JE, Sen S, Dehbi HM, et al. Use of the instantaneous wavefree ratio or fractional flow reserve in PCI[J]. NEngl J Med, 2017(376):1824-1834.
[8] Gotberg M,Christiansen EH,Gudmundsdottir IJ,et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI[J]. N Engl J Med,2017(376):1813-1823.
[9] Pijls NH,De Bruyne B,Peels K,et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenosis[J].N Engl J Med,1996(334):1703-1708.
[10] Musto C,De Felice F,Rigattieri S,et al. Instantaneous wave-freeratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction:The WAVE study[J]. Am Heart J,2017(193):63-69.
[11] Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med,2009,360(3):213-224.
[12] Ali ZA,Maehara A, Genereux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation(ILUMIENⅢ:OPTIMIZE PCI):A randomised controlled trial[J]. Lancet, 2016(388):2618-2628.
[13] Park SJ, Kim YH, Park DW, et al. Impact of intravascular ultrasoundguidance on long-term mortality in stenting for unprotected left main coronary artery stenosis[J]. CircCardiovasc Interv,2009(2):167-177.
[14] Fassa AA,Wagatsuma K,Higano ST,et al. Intravascular ultrasoundguided treatment for angiographically indeterminate left main coronary artery disease:A long-term follow-up study[J]. J Am CollCardiol,2005(45):204-211.
[15] Park SJ,Ahn JM,Kang SJ,et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis[J]. JACC Cardiovasc Interv,2014(7):868-874.
[16] Sianos G,Morel MA,Kappetein AP,et al. The SYNTAX Score:An angiographic tool grading the complexity of coronary artery disease[J]. EuroIntervention,2005(1):219-227.
[17] Stone GW,Sabik JF,Serruys PW,et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease[J]. N Engl J Med,2016,375(23):2223-2235.
[18] M(a|¨)kikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis(NOBLE):aprospective, randomised,open-label, non-inferiority trial[J]. Lancet, 2016,388(10061):2743-2752.
[19] Valgimigli M,Gagnor A,Calabro P,et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management:A randomised multicentre trial[J]. Lancet, 2015(385):2465-2476.
[20] Byme RA,Serruys PW,Baumbach A,et al. Report of a EuropeanSociety of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe:Executive summary[J]. Eur Heart J,2015(36):2608-2620.
[21] Bonaa KH,Mannsverk J,Wiseth R,et al. Drug-eluting or bare-metal stents for coronary artery disease[J]. NEngl J Med,2016(375):1242-1252.
[22] Maeng M,Holm NR,Erglis A,et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions:Nordic Bifurcation Study 5-year follow-up results[J]. J Am Coll Cardiol,2013(62):30-34.
[23] Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions:The British Bifurcation Coronary Study:Old, new, and evolving strategies[J]. Circulation,2010(121):1235-1243.
[24] Behan MW,Holm NR,Curzen NP,et al. Simple or complex stenting for bifurcation coronary lesions:A patient-level pooled-analysis of the Nordic Bifurcation Study and the BritishBifurcation Coronary Study[J]. Circ Cardiovasc Interv,2011(4):57-64.
[25] Chen SL,Santoso T, Zhang JJ,et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions:Results from the DKCRUSH-II(Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions)trial[J]. J Am Coll Cardiol,2011(57):914-920.
[26] Katritsis DG, Siontis GC, Ioannidis JP. Double versus single stenting for coronary bifurcation lesions:A meta-analysis[J]. Circ Cardiovasc Interv,2009(2):409-415.
[27] Chen SL, Zhang JJ, Han Y, et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions:DKCRUSH-V randomized trial[J]. J Am Coll Cardiol,2017(70):2605-2617.
[28] Thiele H, Akin I, Sandri M,et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock[J]. N EnglJ Med,2017(377):2419-2432.
[29] Montalescot G,Sechtem U,Achenbach S,et al. 2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J,2013,34(38):2949-3003.
[30] Chang M, Lee CW, Ahn JM, et al. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantationfor non-ST-elevation acute coronary syndrome[J]. Am J Cardiol,2017(120):380-386.
[31] Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction:Quantitative review of randomised trials[J]. Lancet,2006(367):579-588.
[32] Boersma E, Primary Coronary Angioplasty vs. Thrombolysis Group.Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients[J]. Eur Heart J,2006(27):779-788.
[33]Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12hours from symptom onset:A randomized controlled trial[J].JAMA,2005(293):2865-2872.
[34] Busk M,Kaltoft A, Nielsen SS,et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs 12-72 h[J]. Eur Heart J,2009(30):1322-1330.
[35] Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading:A randomized double-blind trial[J]. Circulation,2009(119):1933-1940.
[36] Dans AL,Connolly SJ,Wallentin L,et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy(RE-LY)trial[J].Circulation,2013(127):634-640.
[37] Kopin D,Jones WS,Sherwood MW,et al. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin:Insights from the ARISTOTLE trial[J]. Am Heart J,2018(197):133-141.
[38] Ruff CT,Giugliano RP,Braunwald E,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:A meta-analysis of randomised trials[J].Lancet,2014(383):955-962.
[39] Cannon CP,Bhatt DL,Oldgren J,et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J]. N Engl J Med,2017(377):1513-1524.
[40] Ranucci M,Colella D,Baryshnikova E,et al. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery[J]. Br J Anaesth,2014(113):970-976.
[41] Steg PG,Bhatt DL,Hamm CW,et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions:A pooled analysis of patient-level data[J]. Lancet,2013(382):1981-1992.
[42] aul TK,Bhatheja S,Panchal HB,et al. Outcomes of saphenous vein graf tintervention with and without embolic protection device:A comprehensive review and meta-analysis[J]. Circ Cardiovasc Interv, 2017(10):5538.
[43] Piepoli MF,Hoes AW,Agewall'S,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice:The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention&Rehabilitation(EACPR)[J]. Eur Heart J,2016(37):2315-2381.
[2] Montalescot G,Sechtem U,Achenbach S,et al. 2013 ESC guidelines on the management of stable coronary artery[J]. Eur Heart J,2013(34):2949-3003.
[3] Bonow RO,Maurer G,Lee KL,et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction[J].NEnglJMed,2011(364):1617-1625.
[4] Allman KC,Shaw LJ,Hachamovitch R,et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction:A meta-analysis[J]. J Am Coll Cardiol,2002(39):1151-1158.
[5] Ling LF,Marwick TH,Flores DR,et al. Identification of therapeutic benefit from revascularization inpatients with left ventricular systolic dysfunction:Inducible ischemia versus hibernating myocardium[J]. Circ Cardiovasc Imaging,2013,6(3):363-372.
[6] Pijls NH,van Schaardenburgh P,Manoharan G,et al. Percutaneous coronaryintervention of functionally nonsignificant stenosis:5-year follow-up of the DEFER Study[J]. J Am CollCardiol, 2007(49):2105-2111.
[7] Davies JE, Sen S, Dehbi HM, et al. Use of the instantaneous wavefree ratio or fractional flow reserve in PCI[J]. NEngl J Med, 2017(376):1824-1834.
[8] Gotberg M,Christiansen EH,Gudmundsdottir IJ,et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI[J]. N Engl J Med,2017(376):1813-1823.
[9] Pijls NH,De Bruyne B,Peels K,et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenosis[J].N Engl J Med,1996(334):1703-1708.
[10] Musto C,De Felice F,Rigattieri S,et al. Instantaneous wave-freeratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction:The WAVE study[J]. Am Heart J,2017(193):63-69.
[11] Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med,2009,360(3):213-224.
[12] Ali ZA,Maehara A, Genereux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation(ILUMIENⅢ:OPTIMIZE PCI):A randomised controlled trial[J]. Lancet, 2016(388):2618-2628.
[13] Park SJ, Kim YH, Park DW, et al. Impact of intravascular ultrasoundguidance on long-term mortality in stenting for unprotected left main coronary artery stenosis[J]. CircCardiovasc Interv,2009(2):167-177.
[14] Fassa AA,Wagatsuma K,Higano ST,et al. Intravascular ultrasoundguided treatment for angiographically indeterminate left main coronary artery disease:A long-term follow-up study[J]. J Am CollCardiol,2005(45):204-211.
[15] Park SJ,Ahn JM,Kang SJ,et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis[J]. JACC Cardiovasc Interv,2014(7):868-874.
[16] Sianos G,Morel MA,Kappetein AP,et al. The SYNTAX Score:An angiographic tool grading the complexity of coronary artery disease[J]. EuroIntervention,2005(1):219-227.
[17] Stone GW,Sabik JF,Serruys PW,et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease[J]. N Engl J Med,2016,375(23):2223-2235.
[18] M(a|¨)kikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis(NOBLE):aprospective, randomised,open-label, non-inferiority trial[J]. Lancet, 2016,388(10061):2743-2752.
[19] Valgimigli M,Gagnor A,Calabro P,et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management:A randomised multicentre trial[J]. Lancet, 2015(385):2465-2476.
[20] Byme RA,Serruys PW,Baumbach A,et al. Report of a EuropeanSociety of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe:Executive summary[J]. Eur Heart J,2015(36):2608-2620.
[21] Bonaa KH,Mannsverk J,Wiseth R,et al. Drug-eluting or bare-metal stents for coronary artery disease[J]. NEngl J Med,2016(375):1242-1252.
[22] Maeng M,Holm NR,Erglis A,et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions:Nordic Bifurcation Study 5-year follow-up results[J]. J Am Coll Cardiol,2013(62):30-34.
[23] Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions:The British Bifurcation Coronary Study:Old, new, and evolving strategies[J]. Circulation,2010(121):1235-1243.
[24] Behan MW,Holm NR,Curzen NP,et al. Simple or complex stenting for bifurcation coronary lesions:A patient-level pooled-analysis of the Nordic Bifurcation Study and the BritishBifurcation Coronary Study[J]. Circ Cardiovasc Interv,2011(4):57-64.
[25] Chen SL,Santoso T, Zhang JJ,et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions:Results from the DKCRUSH-II(Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions)trial[J]. J Am Coll Cardiol,2011(57):914-920.
[26] Katritsis DG, Siontis GC, Ioannidis JP. Double versus single stenting for coronary bifurcation lesions:A meta-analysis[J]. Circ Cardiovasc Interv,2009(2):409-415.
[27] Chen SL, Zhang JJ, Han Y, et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions:DKCRUSH-V randomized trial[J]. J Am Coll Cardiol,2017(70):2605-2617.
[28] Thiele H, Akin I, Sandri M,et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock[J]. N EnglJ Med,2017(377):2419-2432.
[29] Montalescot G,Sechtem U,Achenbach S,et al. 2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J,2013,34(38):2949-3003.
[30] Chang M, Lee CW, Ahn JM, et al. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantationfor non-ST-elevation acute coronary syndrome[J]. Am J Cardiol,2017(120):380-386.
[31] Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction:Quantitative review of randomised trials[J]. Lancet,2006(367):579-588.
[32] Boersma E, Primary Coronary Angioplasty vs. Thrombolysis Group.Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients[J]. Eur Heart J,2006(27):779-788.
[33]Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12hours from symptom onset:A randomized controlled trial[J].JAMA,2005(293):2865-2872.
[34] Busk M,Kaltoft A, Nielsen SS,et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs 12-72 h[J]. Eur Heart J,2009(30):1322-1330.
[35] Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading:A randomized double-blind trial[J]. Circulation,2009(119):1933-1940.
[36] Dans AL,Connolly SJ,Wallentin L,et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy(RE-LY)trial[J].Circulation,2013(127):634-640.
[37] Kopin D,Jones WS,Sherwood MW,et al. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin:Insights from the ARISTOTLE trial[J]. Am Heart J,2018(197):133-141.
[38] Ruff CT,Giugliano RP,Braunwald E,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:A meta-analysis of randomised trials[J].Lancet,2014(383):955-962.
[39] Cannon CP,Bhatt DL,Oldgren J,et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J]. N Engl J Med,2017(377):1513-1524.
[40] Ranucci M,Colella D,Baryshnikova E,et al. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery[J]. Br J Anaesth,2014(113):970-976.
[41] Steg PG,Bhatt DL,Hamm CW,et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions:A pooled analysis of patient-level data[J]. Lancet,2013(382):1981-1992.
[42] aul TK,Bhatheja S,Panchal HB,et al. Outcomes of saphenous vein graf tintervention with and without embolic protection device:A comprehensive review and meta-analysis[J]. Circ Cardiovasc Interv, 2017(10):5538.
[43] Piepoli MF,Hoes AW,Agewall'S,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice:The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention&Rehabilitation(EACPR)[J]. Eur Heart J,2016(37):2315-2381.